The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: David Michael Westenberg - Guggenheim Securities, LLC, Research Division - Analyst
: Congrats on a great year. Can you give us a little bit of flavor on where Trio is taking share from? I think you mentioned there's some new to the
category, but I'm just kind of getting the trend and the flavor, is that legacy, just legacy flee and tick? I mean, what component is heartworm? And
basically, what I'm trying to do is get a good sense of how big this can grow in terms of both the heartworm market and the flee and tick market?
And then just a second related question on Trio. Is there any synergies, particularly on the sales synergy from the direct-to-consumer marketing
campaigns that might be able to benefit maybe derm or maybe even there's a cost synergy?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 16, 2021 / 1:30PM, ZTS.N - Q4 2020 Zoetis Inc Earnings Call
Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst
: Going back to the diagnostics field. Glenn, you mentioned the growth rate there, I think, 20-plus percent. Can you talk about to what degree that
rate is influenced by M&A, if at all? And maybe more broadly about your strategy there, clearly, there's an element of sort of building and catching
up, but I'm also curious on sort of how you're trying to differentiate or leapfrog competition broadly from a diagnostics standpoint? And then,
Glenn, are you seeing any signs of upward pressure on key input costs as the world thinks about commodity price inflation or at least the potential
for it?
|
